close

Agreements

Date: 2017-06-06

Type of information: Nomination

Compound:

Company: Axovant Sciences (USA - NY)

Therapeutic area: CNS diseases - Neurological diseases

Type agreement: nomination

Action mechanism:

Disease:

Details:

  • • On June 6, 2017, Axovant Sciences announced that it has appointed Patrick Machado to its Board of Directors effective as of June 15, 2017, while Lawrence Olanoff, MD, and Gary Pisano, Ph.D., have stepped down as directors effective as of the June 1, 2017 board meeting.
  • Mr. Machado was a co-founder of Medivation and served as its Chief Financial Officer from 2004 to 2014, as well as its Chief Business Officer from 2009 to 2014. He also served as a director of Medivation from April 2014 through September 2016. Mr. Machado currently serves on the boards of directors of several other biopharmaceutical companies, including Roivant Sciences, the majority controlling shareholder of Axovant Sciences.
  • Mr. Machado graduated from Santa Clara University summa cum laude with a Bachelor of Arts degree in German and a Bachelor of Science degree in Economics, and received his Juris Doctorate from Harvard Law School.

Financial terms:

Latest news:

Is general: Yes